Carcinoma, Non-Small-Cell Lung: all 6,645 studies

Page 35 of 67. Open to participants first (1,667), then studies with results posted, then the rest; newest registration first within each.

• A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung CancerTerminatedNCT05662670Phase 1/2
• A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid TumorsActive, not recruitingNCT05653882Phase 1
• A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast CancerActive, not recruitingNCT05653752Phase 1
• Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung CancerTerminatedNCT05652868Phase 1
• Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid TumorsActive, not recruitingNCT05651022Phase 1/2
• ELVN-002 in HER2 Mutant Non-Small Cell Lung CancerActive, not recruitingNCT05650879Phase 1
• First in Human Study of AZD9592 in Solid TumorsActive, not recruitingNCT05647122Phase 1
• MYLUNG Consortium Study Protocol 2Active, not recruitingNCT05644808
• Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung CancerSuspendedNCT05642195Phase 1/2
• Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLCCompletedNCT05637580
• A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung CancerActive, not recruitingNCT05635708Phase 2
• Perceptions on Expected Outcomes of Immunotherapy in Advanced Cancer Patients With Poor Performance StatusCompletedNCT05634551
• Study of Novel Treatment Combinations in Patients With Lung CancerActive, not recruitingNCT05633667Phase 2
• Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung StudyActive, not recruitingNCT05633602Phase 3
• Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal CancerTerminatedNCT05631574Phase 1
• Phase I Study of the BBP-398 in Patients With Advance Solid TumorsTerminatedNCT05621525Phase 1
• Upfront Resection of Locally Advanced NSCLC Followed by ChemoradiotherapyStatus unknownNCT05620199Not applicable
• ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung CancersTerminatedNCT05616624Phase 1/2
• A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid TumorsActive, not recruitingNCT05614102Phase 1
• Mobile Health Application of Disease Self-Management in Non-Small Cell Lung Cancer Patients During Targeted TherapyStatus unknownNCT05611450Not applicable
• Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)Active, not recruitingNCT05609968Phase 3
• Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C MutationActive, not recruitingNCT05609578Phase 2
• Exercise Prehabilitation for Patients With NSCLC Before SurgeryCompletedNCT05608759Not applicable
• Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)Active, not recruitingNCT05607550Phase 3
• Establishing Clinical Utility Evidence to Support Coverage and Reimbursement for Venn Biosciences' Dawn TestWithdrawnNCT05603299Not applicable
• Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)Status unknownNCT05603013Phase 2
• Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKIActive, not recruitingNCT05601973Phase 2
• Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)Active, not recruitingNCT05599789Phase 2
• A Study of Nivolumab, Ipilimumab, and Chemotherapy in Participants With Non-small Cell Lung CancerCompletedNCT05599685
• Intrathecal Double Checkpoint InhibitionActive, not recruitingNCT05598853Phase 1
• Study of DF9001 in Patients With Advanced Solid TumorsCompletedNCT05597839Phase 1/2
• Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung CancerStatus unknownNCT05588206Phase 1/2
• A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid TumorsActive, not recruitingNCT05585320Phase 1/2
• Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid TumorsCompletedNCT05585034Phase 1
• Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLCTerminatedNCT05583188Phase 4
• Phase 1 Study of Oral RH324 in Advanced Non-Small Cell Lung CancerStatus unknownNCT05580172Phase 1
• A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK PathwayTerminatedNCT05578092Phase 1
• First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm TrialStatus unknownNCT05574998Phase 2
• A Study to Investigate LYL845 in Adults With Solid TumorsTerminatedNCT05573035Phase 1
• A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid TumorsTerminatedNCT05571839Phase 1
• Investigating the Feasibility of a Physical Activity (tele)coaching Intervention in Patients with Non-small Cell Lung Cancer: an Explorative StudyCompletedNCT05569291Not applicable
• CISH Inactivated TILs in the Treatment of NSCLCWithdrawnNCT05566223Phase 1/2
• Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or LymphomasActive, not recruitingNCT05565417Phase 1/2
• A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung CancerActive, not recruitingNCT05565378Phase 2
• 89Zr-girentuximab for PET Imaging of CAIX Positive Solid TumorsTerminatedNCT05563272Phase 2
• Optimizing Endobronchial Ultrasound Sampling for Molecular Markers for NSCLCActive, not recruitingNCT05560776Not applicable
• A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815Active, not recruitingNCT05557045Phase 1
• Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)Active, not recruitingNCT05555732Phase 3
• PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell LungActive, not recruitingNCT05553834Phase 2
• Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLCCompletedNCT05549037Phase 3
• A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)CompletedNCT05546905
• Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRmActive, not recruitingNCT05546866Phase 2
• Study of Oral MRT-2359 in Selected Cancer PatientsActive, not recruitingNCT05546268Phase 1/2
• A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersActive, not recruitingNCT05544929Phase 1
• A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid TumorsCompletedNCT05538572Phase 1
• A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsActive, not recruitingNCT05538130Phase 1
• A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid TumorsActive, not recruitingNCT05537740Phase 1
• Tissue Eosinophils in Non-Small Cell Lung Cancer (the TEN Study)Active, not recruitingNCT05537701
• Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung CancerStatus unknownNCT05529355Phase 2
• Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)Active, not recruitingNCT05520099
• A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLCCompletedNCT05519865Phase 2
• Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung CancerCompletedNCT05517083Not applicable
• Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung CancerStatus unknownNCT05513664
• Prognostic Value of Body Composition in Lung CancerCompletedNCT05512429
• Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent MutationsStatus unknownNCT05507606Phase 2
• Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT05502237Phase 3
• the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug ChemotherapyStatus unknownNCT05497076
• Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 MutationActive, not recruitingNCT05491811Phase 2
• Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung CancerWithdrawnNCT05488626Not applicable
• A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05488314Phase 1/2
• A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C MutationActive, not recruitingNCT05485974Phase 1
• Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT05485350Phase 2
• Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung CancerWithdrawnNCT05481775Phase 2
• Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid TumorsCompletedNCT05479812Phase 1
• Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (ELEPHAS-01)Active, not recruitingNCT05478538
• Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain MetastasesTerminatedNCT05477615Phase 2
• Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung CancerStatus unknownNCT05472467Phase 2
• Efficacy and Safety of Perioperative Use of Breztri Aerosphere to Relieve Cough After LobectomyStatus unknownNCT05472350Not applicable
• F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung CancerStatus unknownNCT05468294Phase 1/2
• A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid TumorsTerminatedNCT05462873Phase 1
• Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsActive, not recruitingNCT05462717Phase 1
• Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)CompletedNCT05461430
• Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 InhibitorsStatus unknownNCT05460481Phase 2
• Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD EvaluationStatus unknownNCT05460195Phase 2
• Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLCStatus unknownNCT05458726Phase 2
• A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in RussiaActive, not recruitingNCT05456867
• Effect and Long-Term Outcomes of Indocyanine Green Fluorescence Imaging Method Versus Modified Inflation-Deflation Method in Identification of Intersegmental Plane（IMPLANE-0529）CompletedNCT05453721Not applicable
• A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based ChemotherapyActive, not recruitingNCT05450692Phase 3
• Association Between the Results of Specific Genetic Tests and the Efficacy of Targeted Therapies in PatientsCompletedNCT05450081
• Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLCStatus unknownNCT05448781Phase 2
• Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC RegimenTerminatedNCT05443971Phase 1
• TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT05441956Phase 1
• Palliative RadIotherapy of Multiple Metastatic Sites Before First Line of Systemic Therapy With Immune Checkpoint Inhibitors and Chemotherapy in Metastatic Non-Small-Cell Lung CancerCompletedNCT05440916Phase 2
• Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping MutationTerminatedNCT05435846Phase 1
• Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIA-IIIB Resectable NSCLC (FORESEE)Active, not recruitingNCT05430802Phase 2
• Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLCStatus unknownNCT05430386Phase 1
• A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT05429320Phase 2
• TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung CancerCompletedNCT05427305Phase 3
• Deep Learning Signature for Predicting Occult Nodal Metastasis of Clinical N0 Lung CancerStatus unknownNCT05425134
• Osimertinib for NSCLC With Uncommon EGFR MutationsSuspendedNCT05421936

← Carcinoma, Non-Small-Cell Lung overview